Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidatevan der Schans, J., Kotsopoulos, N., Hoekstra, P. J., Hak, E. & Postma, M. J., 29-May-2015, In : PLoS ONE. 10, 5, 15 p., e0127237.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacoepidemiology and Pharmacoeconomics
- Microbes in Health and Disease (MHD)
- Methods in Medicines evaluation & Outcomes research (M2O)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
- Clinical Cognitive Neuropsychiatry Research Program (CCNP)
BACKGROUND: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder in children and adolescents. Immediate-release methylphenidate (IR-MPH) is the medical treatment of first choice. The necessity to use several IR-MPH tablets per day and associated potential social stigma at school often leads to reduced compliance, sub-optimal treatment, and therefore economic loss. Replacement of IR-MPH with a single-dose extended release (ER-MPH) formulation may improve drug response and economic efficiency.
OBJECTIVE: To evaluate the cost-effectiveness from a societal perspective of a switch from IR-MPH to ER-MPH in patients who are sub-optimally treated.
METHODS: A daily Markov-cycle model covering a time-span of 10 years was developed including four different health states: (1) optimal response, (2) sub-optimal response, (3) discontinued treatment, and (4) natural remission. ER-MPH options included methylphenidate osmotic release oral system (MPH-OROS) and Equasym XL/Medikinet CR. Both direct costs and indirect costs were included in the analysis, and effects were expressed as quality-adjusted life years (QALYs). Univariate, multivariate as well as probabilistic sensitivity analysis were conducted and the main outcomes were incremental cost-effectiveness ratios.
RESULTS: Switching sub-optimally treated patients from IR-MPH to MPH-OROS or Equasym XL/Medikinet CR led to per-patient cost-savings of €4200 and €5400, respectively, over a 10-year treatment span. Sensitivity analysis with plausible variations of input parameters resulted in cost-savings in the vast majority of estimations.
CONCLUSIONS: This study lends economic support to switching patients with ADHD with suboptimal response to short-acting IR-MPH to long-acting ER-MPH regimens.
|Number of pages||15|
|Publication status||Published - 29-May-2015|
- DEFICIT-HYPERACTIVITY DISORDER, MULTIMODAL TREATMENT, ADHD, NETHERLANDS, EPIDEMIOLOGY, UTILITIES, EFFICACY, PATTERNS, OUTCOMES, LIFE